Tislelizumab combined with Lenvatinib

DRUG2 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Hong Wu

Conditions

Initially Unresectable Hepatocellular CarcinomaResectable Hepatocellular Carcinoma

Phase 2

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Tianjin Medical University Cancer Institute and HospitalResectable Hepatocellular Carcinoma

Start: 2021-04-30End: 2024-04-30Target: 30Updated: 2021-04-08

Unknown Phase

Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC

Not yet recruitingNCT07480382

Hong WuInitially Unresectable Hepatocellular Carcinoma

Start: 2026-04-01End: 2028-06-30Target: 30Updated: 2026-03-18

Related Papers

Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial.

2026-01-08

A prospective, single-arm, phase II clinical study of tislelizumab in combination with lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with high risk of recurrence.

Journal of Clinical Oncology2023-06-0111 citations